Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Takeda Pharmaceutical Co Ltd, an institutional investment manager based in Tokyo, Japan. The report covers the calendar quarter ended December 31, 2024, and was signed on February 12, 2025, by Amit Singh, Senior Vice President and Head of Treasury.
Key Financial Metrics
As a Form 13F filing, this document discloses equity holdings rather than the company's operational financial performance. Consequently, revenue, profit, cash flow, margins, and debt metrics for Takeda Pharmaceutical Co Ltd are not reported in this text.
- Total Value of Reported Holdings: $26,564,014
- Number of Holdings Reported: 12
- Other Included Managers: 1 (Takeda Vaccines, Inc.)
Material Changes
The filing text does not provide comparative data for the prior period; therefore, material changes in holdings value or composition cannot be determined from this summary alone.
Guidance, Outlook, and Risks
This filing type does not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding the company's business operations. It strictly lists securities held for investment purposes.
Investor Verification Checklist
- Verify the specific 12 equity positions held by Takeda Pharmaceutical Co Ltd in the full Schedule 13F-HR to understand the portfolio composition.
- Confirm the relationship and reporting structure between Takeda Pharmaceutical Co Ltd and the included manager, Takeda Vaccines, Inc.
- Note that this filing reflects investment holdings only and does not represent Takeda's own financial health or operational results.